Skip to Content
Global News Select

Vanda Pharmaceuticals Shares Jump 17% After FDA Approved Fanapt for Bipolar I Disorder

By Sabela Ojea


Shares of Vanda Pharmaceuticals jumped 17% to $4.58 in post-market trading after the company said the Food and Drug Administration approved Fanapt to treat manic or mixed episodes associated with bipolar I disorder in adults.

The biopharmaceutical company said Tuesday the latest marketing approval increases the commercial opportunity of the treatment.

Fanapt has been used for the acute treatment of patients with schizophrenia since its FDA approval in 2009.


Write to Sabela Ojea at


(END) Dow Jones Newswires

April 02, 2024 18:59 ET (22:59 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Market Updates

Sponsor Center